Stifel analyst Daniel Arias raised the firm’s price target on 10x Genomics to $57 from $53 and keeps a Buy rating on the shares.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on TXG:
- 10x Genomics price target raised to $58 from $55 at Canaccord
- 10x Genomics price target raised to $57 from $52 at Cowen
- 10x Genomics reports Q4 EPS (15c), consensus (31c)
- 10x Genomics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Outlook for 2023
- Singular Genomics showcases G4 sequencing data with 11 genomics partners